From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

THERAPY FOR CONGENITAL TOXOPLASMOSIS HAS GOOD RESULTS.

Untreated congenital toxoplasmosis usually leaves babies with profound developmental, neurologic, and visual impairment. Treatment regimens have varied, but this major study shows good outcomes in the majority of babies treated with pyrimethamine and sulfadiazine. Physicians treated 36 babies with symptomatic congenital toxoplasmosis with the two drugs for about one year, and followed them for up to 10 years. Within months of treatment initiation, all signs of active toxoplasmosis resolved (e.g., seizures, CSF abnormalities, and chorioretinitis). Abnormalities on cranial imaging resolved or diminished in 15 of 21 infants. Sixteen of the 36 children had normal neurologic exams on every follow-up visit. IQ scores were normal in two thirds of the children, but were significantly lower than those of uninfected siblings. The most frequent residual finding was visual impairment (found in 58 percent). Infants without hydrocephalus had a good prognosis, as did infants with late-developing, shunt-responsive hydrocephalus, whereas 8 of the 10 babies born with hydrocephalus had severe disabilities. Comment: Because of the relatively small sample and young mean age at follow-up (just over 4 years), these results are preliminary. Still, it is remarkable that two thirds of the children, who would have been expected to be severely retarded, had normal intelligence. The authors urge systematic detection and treatment of toxoplasma infection in pregnant women and their infants.

— RA Dershewitz

Published in Journal Watch General Medicine January 17, 1995

Citation(s):

Roizen N, et al. Neurologic and developmental outcome in treated congenital toxoplasmosis. Pediatrics 1995 Jan 95 11-20.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 1995. Massachusetts Medical Society. All rights reserved.